AOD-9604 vs Semaglutide
Comparison of failed AOD-9604 trials versus proven semaglutide for weight management.
Last updated: January 19, 2026
AOD-9604
Semaglutide
Overview
AOD-9604 failed Phase 2b/3 trials while semaglutide succeeded in becoming an FDA-approved weight loss medication.
Status Comparison
| Aspect | AOD-9604 | Semaglutide |
|---|---|---|
| FDA Status | Failed trials | Approved |
| Trial Result | Did not meet endpoint | Significant efficacy |
| Weight Loss | No significant effect | 14.9% (STEP 1) |
Why AOD-9604 Failed
- Did not separate from placebo
- Mechanism may not translate to humans
- Insufficient effect size
- Development discontinued
Why Semaglutide Succeeded
- Clear mechanism (GLP-1 agonist)
- Robust efficacy signal
- Multiple successful Phase 3 trials
- Cardiovascular benefit demonstrated
Summary
AOD-9604 is an example of a peptide that looked promising preclinically but failed in rigorous human trials. Semaglutide represents successful drug development with proven efficacy.
This comparison is for educational purposes only. AOD-9604 is not approved; semaglutide requires a prescription.
View Full Dossiers
Stay Updated on Peptide Comparisons
Get notified when we publish new comparison dossiers and evidence reviews.
No spam. Unsubscribe anytime.
Disclaimer: This comparison is for educational purposes only and does not constitute medical advice. Individual responses to medications vary. Always consult a qualified healthcare provider before making treatment decisions.